Overview

Addressing Underutilization of Cardioprotective GLP-1 RAs for T2D in Specialty Practice

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

Start Activity

Format

Personalized Education (powered by ACHL CustomED®)

Time to Complete

2.00 hr(s).

Release Date

July 31, 2024

Expires On

July 31, 2025

The complexity of patients with T2D combined with the overwhelming amount of outcomes data complicates the treatment decision matrix exponentially and clinical inertia persists. This self-paced, interactive education includes a learning assessment followed by customizable content repository designed to sharpen your ability to individualize therapeutic targets and glucose-lowering regimens based on multiple factors, including the presence of comorbidities, such as obesity or cardiovascular risk. This unique 2-part activity accommodates the diverse learning needs of the diabetes team to ensure consistent knowledge across clinician types and support optimal care for all patients. Put your knowledge to the test, see how you compare to your peers and create your own customized learning experience!

This activity is intended for endocrinologists, diabetologists, certified diabetes care and education specialists (CDCES), NPs and PAs practicing in the specialty setting.

T2D is associated with comorbidities such as ASCVD, CKD, and obesity, among others, leading to significant morbidity and mortality. Accumulating data from CVOTs have demonstrated the benefits of GLP-1 RAs, not just for glycemic management, but for improving outcomes related to MACEs in those with T2D. Clinical practice guidelines consistently recommend GLP-1 RAs based on their glycemic and nonglycemic effects, and new safety and efficacy data continually advance our understanding of the role of these therapies for patients with T2D. However, clinicians remain challenged to implement GLP-1 RA therapy in clinical practice for patients with T2D, including those with comorbidities who would benefit from the MACE-reducing effects of these therapies. This education is designed to address the needs of endocrinologists, diabetologists, certified diabetes care and education specialists, nurse practitioners, and physician assistants practicing in the specialty setting relating to the use of cardioprotective GLP-1 RAs for T2D.

• Interpret the latest data on glycemic and nonglycemic benefits of the GLP-1 RAs from clinical trials and real-world studies
• Discuss the benefits of earlier treatment intensification with GLP-1 RAs to reduce long-term complications in patients with type 2 diabetes
• Formulate individualized management strategies for type 2 diabetes that account for patient characteristics and clinical targets

Provided by the Association of Diabetes Care & Education Specialists (ADCES) and the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Novo Nordisk.

A large proportion of patients with T2D do not receive guideline-recommended therapy despite the importance of early treatment intensification to reduce complications such as cardiovascular disease. In this activity, customized learning responsive to each learner’s role and educational needs provides targeted content and resources to help clinicians enhance their practices and ensure that patients with T2D receive cardioprotective therapies.

Listen to Dr. Jennifer Green to learn more about the goals and topics of this unique activity.

Kathleen Dungan, MD
Professor
Division of Endocrinology, Diabetes & Metabolism
The Ohio State University
Columbus, OH

Jennifer B. Green, MD

Professor of Medicine

Duke University Medical Center

Division of Endocrinology, Metabolism and Nutrition

Durham, NC

Debbie Hinnen APN, BC-ADM, CDCES, FADCES, FAAN

Advanced Practice Nurse and Certified Diabetes Care and Education Specialist

University of Colorado Health and Tri-Lakes Cares

Colorado Springs, CO

Per the ACCME’s Standards For Integrity and Independence in an Accredited Continuing Education, the Association of Diabetes Care & Education Specialists (ADCES) requires all individuals that have a position to control content disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Kathleen Dungan, MD

Consulting Agreements: Dexcom, Inc., Eli Lilly, Elsevier, Insulet Corporation, Oppenheimer & Co., Inc.

Royalty: UpToDate

Speakers' Bureau: Medscape, Med Learning Group

Jennifer B. Green, MD

Sources of Funding for Research: Bluedrop, Boehringer Ingelheim, Lilly, Merck, Roche

Consulting Agreements: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Merck, Novo

Nordisk, Sanofi

Debbie Hinnen APN, BC-ADM, CDCES, FADCES, FAAN

Speakers' Bureau: Eli Lilly, Intuity Medical, Inc., Novo Nordisk, Sanofi

ADCES and ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ADCES and ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: None

To receive credit, learners are required to complete the assessment, view the content repository, and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

In support of improving patient care, The Association of Diabetes Care & Education Specialists is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The Association of Diabetes Care & Education Specialists designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Universal Activity Number is JA4008258-9999-24-278-HO1-P. This application-based activity has been approved for 2.0 contact hour(s).

The Association of Diabetes Care & Education Specialists designates this activity for a maximum of 2.0 ANCC contact hours.

Per the American Academy of Nurse Practitioners Certification Board, nurse practitioners may claim contact hours from ANCC or CME from AAPA. Pharmacotherapeutic hours are listed under the ANCC accreditation statement on your continuing education statement of credit upon completion.

The Association of Diabetes Care & Education Specialists has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until July 15, 2025. PAs should only claim credit commensurate with the extent of their participation.

Commission on Dietetic Registration (CDR): CDR Credentialed Practitioners will receive 2.0 Continuing Professional Education units (CPEUs) for completing this activity. Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed commensurate with participation in contact hours (One 60-minute hour = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner’s discretion.

Certified Diabetes Care and Education Specialists: To satisfy the requirements for renewal of certification for the Certification Board for Diabetes Care and Education (CBDCE), continuing education activities must be diabetes related and approved by a provider on the CBDCE list of Approved Providers (http://www.cbdce.org). CBDCE does not approve continuing education. The Association of Diabetes Care & Education Specialists is on the CBDCE list of Approved Providers.

Karen Catino
kcatino@achlcme.org

Overview

Addressing Underutilization of Cardioprotective GLP-1 RAs for T2D in Specialty Practice

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Activity Overview

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities